Users Online: 137
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 9  |  Issue : 1  |  Page : 59-61

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

1 Department of Medical Oncology, Sum Hospital, Bhubaneswar, Odisha, India
2 Department of Medical Oncology, RCC, Patna, Bihar, India
3 Department of Medical Oncology, Yashoda Hospital, Secunderabad, Telangana, India
4 Department of Medical Oncology, Asian Cancer Institute, Mumbai, Maharashtra, India
5 Department of Medical Oncology, Kerala Institute of Medical Sciences, Trivandrum, Kerala, India
6 Department of Medical Oncology, Apollo Specialty Hospital, Chennai, Tamil Nadu, India
7 Department of Medical Oncology, Mohandai Oswal Hospital, Ludhiana, Punjab, India
8 Department of Medical Oncology, BLK Superspeciality Hospital, Delhi, NCR, India
9 Department of Medical Oncology, Naik Hospital, Baroda, Gujarat, India
10 Department of Medical Oncology, Mumbai Oncocare Center, Mumbai, Maharashtra, India
11 Department of Medical Oncology, Apollo Hospital, Kolkata, West Bengal, India
12 Department of Pain and Palliative Care, Saroj Gupta Cancer Hospital, Kolkata, West Bengal, India
13 Department of Medical Oncology, Batra Cancer Center, Delhi, NCR, India
14 Department of Medical Oncology, Fortis Hospital, Mumbai, Maharashtra, India
15 Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana, India
16 Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
17 Department of Medical Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujarat, India

Correspondence Address:
Prof. Purvish M Parikh
Department of Medical Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sajc.sajc_246_19

Rights and Permissions

Introduction: Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use. Methods: We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma. Results: There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity. Conclusion: Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded108    
    Comments [Add]    

Recommend this journal